Keywords: UCB, Neupro, Parkinson's disease, RLS, USA, FDA
FDA approves UCB drug Neupro for PD and RLS
Article | 03 April 2012
Belgian drugmaker UCB (Euronext Brussels: UCB) said yesterday that the US Food and Drug Administration has approved Neupro (rotigotine transdermal ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
